Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TARA | EFFECT | bearish | 5/10 | Protara Therapeutics' registration statement on Form S-3 (File No. 333-295862) was declared effective on May 22, 2026. T | May 26, 2026 |
| SNYR | EFFECT | bearish | 7/10 | The SEC declared effective Synergy CHC Corp.'s S-1 registration (File No. 333-295964) on May 22, 2026, covering the resa | May 26, 2026 |
| KPHMW | EFFECT | bearish | 6/10 | Kiora Pharmaceuticals' S-3 shelf registration (File No. 333-295994) became effective on May 22, 2026, enabling the resal | May 26, 2026 |
| CPIX | DEFM14A | bullish | 7/10 | Cumberland Pharmaceuticals is seeking shareholder approval to sell its FDA-approved commercial product portfolio (Acetad | May 26, 2026 |
| KURA | PRESS-RELEASE | bullish | 7/10 | Kura Oncology reported positive first-in-human Phase 1a data for darlifarnib plus adagrasib in KRAS G12C-mutated solid t | May 26, 2026 |
| SCLXW | EFFECT | bearish | 6/10 | Scilex Holding Co's Form S-3 shelf registration (File No. 333-295109) was declared effective by the SEC on May 22, 2026. | May 26, 2026 |
| EDIT | PRESS-RELEASE | bullish | 7/10 | Editas Medicine presented preclinical data for EDIT-401 at the EAS Congress, showing a single dose achieved ~90% mean re | May 26, 2026 |
| BTAIQ | CLUSTER | bearish | 5/10 | Three top insiders at BioXcel Therapeutics (CEO, CFO, and another executive) collectively sold $35.6K in open-market sha | May 22, 2026 |
| MRNA | CLUSTER | neutral | 2/10 | Two Moderna insiders sold a total of $3.02M in open-market sales over a 7-day window. Director Noubar Afeyan exercised a | May 22, 2026 |
| MDGL | CLUSTER | neutral | 3/10 | Two Madrigal insiders (Director Levy and CMO Soergel) sold a combined $456K in open-market transactions, representing ap | May 22, 2026 |
| CLDI | PRESS-RELEASE | bearish | 7/10 | Calidi Biotherapeutics disclosed an audit report with a going-concern emphasis in its 2025 Form 10-K, required by NYSE A | May 22, 2026 |
| TPST | 8-K | bearish | 8/10 | Tempest Therapeutics received a Nasdaq deficiency letter on May 19, 2026, for failing the minimum stockholders' equity r | May 22, 2026 |
| IOVA | PRESS-RELEASE | neutral | 2/10 | Iovance Biotherapeutics granted inducement stock options covering 93,340 shares to 13 new non-executive employees under | May 22, 2026 |
| MAZE | 8-K | neutral | 2/10 | Maze Therapeutics disclosed the resignation of Amy Bachrodt, Senior Vice President of Finance, effective June 1, 2026. T | May 22, 2026 |
| NGEN | 6-K | bearish | 7/10 | NervGen Pharma announced a $60.0 million underwritten public offering of 24 million common shares and warrants to purcha | May 22, 2026 |
| ABEO | CLUSTER | neutral | 2/10 | Two directors at Abeona Therapeutics sold a total of $180K in open-market transactions within a week of the company's Q1 | May 22, 2026 |
| JAGX | 8-K | bearish | 6/10 | Jaguar Health issued 54,222 common shares to Streeterville Capital in exchange for the cancellation of 7.96 shares of Se | May 22, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three UTHR insiders including the CEO, CFO, and EVP & General Counsel executed a series of option exercises and small op | May 22, 2026 |
| FOXOW | 8-K | bearish | 6/10 | FOXO Technologies settled outstanding obligations with J.H. Darbie by issuing 400 shares of Series D Convertible Preferr | May 22, 2026 |
| TPST | 8-K | bearish | 5/10 | Three board directors (Stephen Brady, Michael Raab, Christine Pellizzari) resigned from Tempest Therapeutics' board effe | May 22, 2026 |
| EXEL | CLUSTER | neutral | 3/10 | Three senior executives at Exelixis (CFO, EVP Commercial, SVP/GC) collectively sold $3.68M in open-market shares within | May 22, 2026 |
| CTXR | S-3 | bearish | 6/10 | Citius Pharmaceuticals filed an S-3 registration statement to register 5,431,473 shares of common stock for resale by se | May 22, 2026 |
| SCNX | 8-K | neutral | 5/10 | Scienture Holdings reported Q1 2026 revenue of ~$56K (up 449% YoY from ~$10K) and gross margin expansion to 95.6%, drive | May 22, 2026 |
| VNRX | 8-K | bearish | 7/10 | VolitionRx disclosed it violated the minimum market capitalization covenant on its $9.9M in aggregate senior secured con | May 22, 2026 |
| ZSQR | 8-K | neutral | 3/10 | Z Squared Inc. (ZSQR) announced that Co-CEO and director Michelle Burke resigned effective May 22, 2026, citing no disag | May 22, 2026 |
| ENSCW | 8-K | bearish | 7/10 | Ensysce Biosciences received a Nasdaq delisting notice on May 21, 2026 for failing to meet the $2.5M stockholders' equit | May 22, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Director Carl Dambkowski and SVP Arjun Agarwal executed derivative exercises and open-market sales, with total open-mark | May 22, 2026 |
| GEVO | CLUSTER | neutral | 2/10 | Two GEVO insiders sold $103K total in a tight 8-day window: President & COO Michael sold $88K (29.8K shares at $2.96) an | May 22, 2026 |
| GEVO | CLUSTER | neutral | 2/10 | Two GEVO insiders (President & COO and Chief Cust Mkt & Brnd Officer) executed open-market sales totaling $103K between | May 22, 2026 |
| PACB | DEFA14A | neutral | 3/10 | Pacific Biosciences of California, Inc. (PACB) filed additional definitive proxy soliciting materials (DEFA14A) on May 2 | May 22, 2026 |